Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Open Access
- 1 July 2010
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 18 (7), 1357-1364
- https://doi.org/10.1038/mt.2010.85
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Decreased C-Reactive Protein Levels in Alzheimer DiseaseJournal of Geriatric Psychiatry and Neurology, 2009
- Development of Lipidoid–siRNA Formulations for Systemic Delivery to the LiverMolecular Therapy, 2009
- An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumorJournal of Controlled Release, 2008
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2008
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory TargetScience, 2008
- Neurotrophic factors in Alzheimer’s disease: role of axonal transportGenes, Brain and Behavior, 2008
- Tumor-targeted Delivery of siRNA by Self-assembled NanoparticlesMolecular Therapy, 2008
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences of the United States of America, 2007